Adaptation of Facilitated Access to Mutual Aid for Community Alcohol and Drug Services (FAMA)

November 16, 2026 updated by: King's College London

Adaptation of a Facilitated Access to Mutual Aid (FAMA) Intervention for Adults Accessing Community Alcohol and Drug Services in England.

Alcohol and other drug (AOD) use disorders are associated with a range of adverse outcomes. Relapse following AOD treatment is common. Attendance at Mutual Aid Groups (MAGs) is associated with improved health outcomes and reduced healthcare utilisation costs. National guidance recommends that clinical staff promote MAG attendance, but few patients are referred to, or attend, MAGs. An intensive referral intervention, developed in the United States of America has been shown to increase engagement with MAGs. The aim of this National Institute for Health Research (NIHR)-funded study is to adapt and test a Facilitated Access to Mutual Aid (FAMA) intervention and staff training for delivery in community AOD services in England.

Phase one of this study consists of qualitative focus groups conducted with staff of community AOD services and adults receiving AOD treatment. Eight focus groups will explore participants' views of MAGs and the existing American FAMA intervention. The FAMA intervention will then be adapted and staff training developed, based on the focus group findings and input from patient and public involvement and engagement (PPIE) groups.

Phase two of this study consists of testing the adapted FAMA intervention. Staff in one community AOD service will receive the newly developed FAMA training. They will deliver FAMA to people who are currently receiving AOD treatment service. Each session will be recorded and the fidelity of intervention delivery will be assessed by the research team using a checklist. Staff and patient feedback will be collected using brief questionnaires in informal feedback sessions. The FAMA intervention will be refined and delivered again with another round of feedback being collected. A final version of the FAMA intervention will then be agreed by the research team and PPIE groups.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

84

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adults aged 18+ years who are accessing AOD treatment and staff, aged 18+ years who are working in paid client facing role in an AOD treatment service.

Description

Phase one (staff) inclusion criteria:

  • Aged 18+ years
  • Currently working in a paid client facing role in an AOD treatment service

Phase one (people accessing AOD treatment) inclusion criteria:

  • Aged 18+ years
  • Currently receiving treatment from an AOD treatment service

Phase two (staff) inclusion criteria:

  • Aged 18+ years
  • Currently working as a keyworker or recover worker in an AOD treatment service

Phase two (people accessing AOD treatment) inclusion criteria:

  • Aged 18+ years
  • Currently receiving treatment from an AOD treatment service
  • On a participating staff member's caseload
  • Not attending MAGs.

Exclusion Criteria:

  • N/A

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: OTHER
  • Time Perspectives: CROSS_SECTIONAL

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Qualitative focus groups
Time Frame: Focus groups will last approximately 90 minutes

Qualitative focus groups

Focus groups will last approximately 90 minutes
Acceptability of Intervention measure (AIM) adapted for FAMA
Time Frame: Maximum 10 weeks from enrolment in the study

Measures whether participants find FAMA to be acceptable

Maximum 10 weeks from enrolment in the study
Feasibility of Intervention (FIM) adapted for FAMA
Time Frame: Maximum 10 weeks from enrolment in the study

Measures whether participants find FAMA to be feasible

Maximum 10 weeks from enrolment in the study
Appropriateness Measure (IAM) adapted for FAMA
Time Frame: Maximum 10 weeks from enrolment in the study

Measures whether participants find FAMA to be appropriate

Maximum 10 weeks from enrolment in the study

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 20, 2026

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 16, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • IRAS 370125

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe